Open an account

Trevena

TRVN · OTC

$0.0005+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.0005

About TRVN

Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. The company is headquartered in Atlanta, Georgia and currently employs 23 full-time employees. The company went IPO on 2014-01-31. The firm has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).

Employees
23
Headquarters
Atlanta, Georgia
Listed
Jan 31, 2014
Sector
Health Care
Industry
Biotechnology
Website
trevena.com

TRVN key statistics

Market cap
432
Price-earnings ratio
0.00
Dividend yield
—
Average volume
405
Volume
25
Open price
$0.0004
High today
$0.0005
Low today
$0.0004
52 Week high
$1.50
52 Week low
$0.0003

Trevena (TRVN) at a glance

As of Oct 19, 2026, Trevena (TRVN) shares are priced at $0.0005, giving the company a market cap of 432 and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.0004 and $0.0005. The current price is 25.0% above the day's low and 0.0% below its high.

Volume so far is 25 shares, below the average of 405 shares a day.

Over the past year Trevena has ranged from $0.0003 to $1.50, and now sits 0% of the way up that range.

Trevena met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q3 FY24 it reported -$5.79 per share against an estimate of -$7.47.

TRVN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 34.3% on average.

  1. Q4 FY22: reported -$18.25 per share against an estimate of -$44.63
  2. Q1 FY23: reported -$20.25 per share against an estimate of -$25.07
  3. Q2 FY23: reported -$17.25 per share against an estimate of -$26.83
  4. Q3 FY23: reported -$14.25 per share against an estimate of -$3.80
  5. Q4 FY23: reported -$26.50 per share against an estimate of -$9.65
  6. Q1 FY24: reported -$9.00 per share against an estimate of -$11.98
  7. Q2 FY24: reported -$5.75 per share against an estimate of -$10.33
  8. Q3 FY24: reported -$5.79 per share against an estimate of -$7.47

TRVN news

  • Avi Kapoor

    Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge

  • Avi Kapoor

    Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher

  • Avi Kapoor

    US Stocks Open Lower; Dow Tumbles Over 150 Points

  • Market-Moving News for October 7th

  • Avi Kapoor

    Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket

Similar companies

Companies in the same industry as Trevena

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.